Vaccines: Study reveals new targets for SARS-coV2 vaccine

June 12, 2020 /PRNewswire/ -- BioValley BIOON/--- we still do not have a vaccine to prevent COVID-19In addition, although several antiviral drugs have been tested, there is no result to show that any one drug is fully effective for the diseaseIn a study just published in the journal Vaccines, researchers at Bar-Ilan University identified a group of potential antigen phenometors from the SARS-CoV-2 protein groupThese epitopes produce antibody-mediated immune responses and cell-mediated immune responsesThe findings of this work may help develop a peptide vaccine for SARS-CoV-2 infection, which could prevent further prevalence of COVID-19Led by DrMilana Frenkel-Morgenstern, head of the Cancer Genomics and Biocomputing Laboratory for Complex Diseases at Bar-Ilan University's Azrieli School of Medicine, the researchers used immunoinformatics-based calculations to mine the protein content of SARS-CoV-2 and then identify the immune advantage epimostes of the virusImmune responsebased to a specific immune advantage epitope causes the host to produce an antibody-mediated immune response and a cell-mediated immune response for such epitopes, ultimately facilitating the rapid and effective elimination of pathogens(Photo source:Researchers including Sumit Mukherjee, Dmitry Tworowski, Rajesh Detroja and Sunanda Biswas Mukherjee identified 15 potential immunogenological regions from three proteins in SARS-CoV-2 and 25 immuno-advantaged tables on other SARS-CoV-2 proteinsTo confirm that these tables can provide broad-spectrum immunity to populations around the world, the researchers identified the percentage of individuals expressing the ability to identify any of these tables as the main tissue compatibility complex (MHC)The results showed that more than 77% of the population worldwide affected by the virus was able to produce an immune response that targeted the above antigen epitopesFurther structural molecular docking analysis estimates the binding interactions of these potential epitopes with human MHCTesting the seven tables selected by using a variety of tools eliminated allergy and toxicity of these tables and showed that they had a lower risk of triggering an autoimmune responseIn summary, these results suggest that these seven tables contribute to the screening of new broad-spectrum vaccines(BioValley Bioon.com) Source: Immunobald epitopes identified for designing peptide-based against SARS-CoV-2 Original origin: Sumitherjee et al, Immunoinformatics and Gear Analysis for Gear for Gear for GearOFor-GearEEpitopes in SARS-CoV-2 DOI: 10.3390/vaccines8020290